Patents by Inventor John V. VOURNAKIS

John V. VOURNAKIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Complexes of IL-15 and IL-15Ralpha and uses thereof
    Patent number: 11110150
    Abstract: The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-?-1-?4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: September 7, 2021
    Assignees: NOVARTIS AG, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Barbara K. Felber, Sergio Finkielsztein, George N. Pavlakis, John V. Vournakis
  • COMPLEXES OF IL-15 AND IL-15RALPHA AND USES THEREOF
    Publication number: 20190290734
    Abstract: The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-?-1-?4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 26, 2019
    Inventors: Barbara K. FELBER, Sergio FINKIELSZTEIN, George N. PAVLAKIS, John V. VOURNAKIS
  • Complexes of IL-15 and IL-15Ralpha and uses thereof
    Patent number: 10265382
    Abstract: The present invention relates to agents that modulate interle?kin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-?-1-?4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: April 23, 2019
    Assignees: NOVARTIS AG, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Barbara K. Felber, Sergio Finkielsztein, George N. Pavlakis, John V. Vournakis
  • IL-15 AND IL-15RALPHA HETERODIMER DOSE ESCALATION REGIMENS FOR TREATING CONDITIONS
    Publication number: 20170202924
    Abstract: Described herein are dose escalation regimens for the administration of complexes comprising interleukin-15 (“IL-15”) covalently or noncovalently bound to IL-15 receptor alpha (“IL-15R?”) to patients in order to enhance IL-15-mediated immune function. In a specific aspect, the dose escalation regimens are useful in the prevention, treatment, and/or management of disorders in which enhancing IL-15-mediated function is beneficial, such as cancer, infectious diseases, immunodeficienices and lymphopenia. In another specific aspect, the dose escalation regimens are useful for eradicating or reducing HIV in HIV-infected patients.
    Type: Application
    Filed: July 28, 2015
    Publication date: July 20, 2017
    Inventors: Barbara K. FELBER, Sergio FINKIELSZTEIN, George N. PAVLAKIS, John V. VOURNAKIS
  • COMPLEXES OF IL-15 AND IL-15RALPHA AND USES THEREOF
    Publication number: 20170151310
    Abstract: The present invention relates to agents that modulate interle?kin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-?-1-?4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
    Type: Application
    Filed: February 3, 2017
    Publication date: June 1, 2017
    Inventors: Barbara K. FELBER, Sergio FINKIELSZTEIN, George N. PAVLAKIS, John V. VOURNAKIS